Decoy Therapeutics Inc.
DCOY | NASDAQ
$1.07
-$0.16 (-13.01%)
At close: Oct 30, 2026, 4:00 PM ET
$1.09
+$0.02 (+1.87%)
Pre-market:
Nov 2, 2026, 6:10 AM ET
Company Profile
Based in Cambridge, Massachusetts, Decoy Therapeutics Inc. is an early-stage biotechnology firm dedicated to tackling critical unmet medical needs. The company employs cutting-edge machine learning and AI technologies, alongside accelerated synthesis methods, to swiftly design, engineer, and manufacture innovative peptide conjugate drug candidates.
Key Executives
| Name | Position |
|---|---|
| Frederick E. Pierce | CEO & Director |
| Barbara Hibner | Chief Scientific Officer |
| Mark J. Rosenblum | Executive VP of Finance & CFO |
| Peter K. Marschel | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 23, 2026 | 8-K | Current Report |
| Sep 15, 2026 | 8-K | Current Report |
| Sep 02, 2026 | 4 | Filing |
| Sep 02, 2026 | 4 | Filing |
| Sep 02, 2026 | 4 | Filing |
| Sep 02, 2026 | 4 | Filing |
| Sep 02, 2026 | 4 | Filing |
| Sep 02, 2026 | 4 | Filing |
| Sep 02, 2026 | 4 | Filing |
| Sep 02, 2026 | 4 | Filing |
Decoy Therapeutics Inc.
| Country | United States |
| IPO Date | Jan 29, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Frederick E. Pierce |
Contact Details
2450 Holcombe Blvd Houston,
Texas 77021 United States
Stock Details
| Ticker Symbol | DCOY |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001615219 |
| CUSIP Number | 79400X602 |
| ISIN Number | US79400X6022 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove DCOY